Viking Therapeutics reports positive Phase 1 data on its obesity candidate VK2735. During the study, participants lost up to 7.9% of their body weight from their baseline. Phase 2 is planned for mid-2023 Viking has five more novel compounds in various stages of clinical trials, which can move the needle on share prices. 5 stocks […]